| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Cell-based therapy for severe hindlimb ischemia is promising in its effectiveness and safety. However, it is necessary to be improved in effects of cell-based therapy for hindlimb ischemia because of its poor therapeutic outcomes. In this study, we investigated if hybrid strategy which is composed by transplantation of preconditioned peripheral blood mononuclear cells and co-administration of apelin was useful therapy for severe hindlimb ischemia. As a result, this hybrid therapeutic strategy resulted in effective maturation of new vessels by cell-based therapy. This strategy will be expected to become novel and low invasive therapeutic approach for severe hindlimb ischemia.
|
